Rhythm Pharmaceuticals (RYTM) Set to Announce Quarterly Earnings on Tuesday

Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) will announce its earnings results after the market closes on Tuesday, November 5th. Analysts expect the company to announce earnings of ($0.80) per share for the quarter. Individual that wish to listen to the company's earnings conference call can do so using this link.

Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.55) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $0.16. The firm had revenue of $29.08 million for the quarter, compared to analyst estimates of $28.79 million. Rhythm Pharmaceuticals had a negative net margin of 254.88% and a negative return on equity of 221.65%. The business's revenue for the quarter was up 51.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.82) EPS. On average, analysts expect Rhythm Pharmaceuticals to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Rhythm Pharmaceuticals Stock Performance

Shares of NASDAQ:RYTM traded up $0.11 during midday trading on Tuesday, reaching $49.54. 236,162 shares of the company's stock were exchanged, compared to its average volume of 530,116. The firm has a market capitalization of $3.02 billion, a PE ratio of -10.49 and a beta of 2.07. The company's 50 day simple moving average is $49.40 and its two-hundred day simple moving average is $44.84. Rhythm Pharmaceuticals has a 12 month low of $21.67 and a 12 month high of $55.64.

Insider Buying and Selling

In other Rhythm Pharmaceuticals news, insider Pamela J. Cramer sold 49,006 shares of the business's stock in a transaction dated Friday, August 9th. The shares were sold at an average price of $45.15, for a total value of $2,212,620.90. Following the completion of the transaction, the insider now directly owns 13,500 shares of the company's stock, valued at approximately $609,525. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, insider Pamela J. Cramer sold 49,006 shares of Rhythm Pharmaceuticals stock in a transaction on Friday, August 9th. The stock was sold at an average price of $45.15, for a total value of $2,212,620.90. Following the completion of the sale, the insider now directly owns 13,500 shares of the company's stock, valued at approximately $609,525. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Lynn A. Tetrault sold 4,300 shares of the company's stock in a transaction on Monday, August 26th. The shares were sold at an average price of $50.01, for a total value of $215,043.00. Following the transaction, the director now directly owns 3,000 shares in the company, valued at $150,030. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 109,857 shares of company stock worth $5,325,446 in the last 90 days. Corporate insiders own 5.60% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on RYTM. JMP Securities started coverage on Rhythm Pharmaceuticals in a report on Tuesday, September 17th. They set an "outperform" rating and a $64.00 price objective on the stock. Bank of America boosted their price target on Rhythm Pharmaceuticals from $48.00 to $52.00 and gave the company a "neutral" rating in a research note on Monday, October 14th. Needham & Company LLC reiterated a "buy" rating and set a $55.00 price objective on shares of Rhythm Pharmaceuticals in a research note on Wednesday, August 7th. Guggenheim started coverage on Rhythm Pharmaceuticals in a report on Monday, October 21st. They set a "buy" rating and a $70.00 price objective for the company. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $64.00 target price on shares of Rhythm Pharmaceuticals in a report on Friday. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, Rhythm Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $60.33.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.